Novartis (NVS) is facing a "sharp deceleration" in growth in mid-2025 amid patent expiries and limited newsflow levers, UBS Securities said in a Wednesday note.
According to UBS, Novartis' 2025 guidance "illustrates" headwinds from mid-year, with earnings before interest and taxes to grow by high teens in H1 and then slow to low to mid-single digits in H2.
Novartis enters a period of patent expiries and has limited pipeline readouts this year, but its in-market portfolio still has the potential to deliver on the company's mid-term growth targets, UBS said.
UBS downgraded the stock to neutral from buy.
NVS shares were 0.8% higher in recent trading.
Price: 107.89, Change: +0.89, Percent Change: +0.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.